Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2021 / Articles / Feb / The Inhalation Advantage
Discovery & Development Formulation Drug Delivery Drug Delivery Sponsored

The Inhalation Advantage

Faster and more affordable development of inhaled medicines

02/04/2021 1 min read

Sponsored By

Share

Vectura has more than 20 years’ experience in helping customers bring inhaled medicines to the market, and integrates formulation, device and development capabilities to offer a broad range of services to accelerate inhaled products through the phases of drug development. Having expertise in product formulation and device development across a number of platforms offers customers both flexibility and continuity, forging true collaborative partnerships to combine the right drug with the right device.

The trend within the industry to find new uses for old drugs has increased, and might take a drug already approved for one indication, and find utility in another; or create a new formulation to allow administration via a different route for the same indication. Alternatively, an existing drug may have its product profile improved or altered, while keeping the same administration route. Either way, as well as providing advantages for patients, it can offer new intellectual property coverage, driving additional revenue for innovators with lower risk and faster entry to market.

Inhaled delivery offers opportunities for improved dosing, simpler, less invasive administration, enhanced patient adherence, and product lifecycle management. By repurposing known drugs and leveraging pre-existing drug safety data, manufacturers benefit from shorter, less costly and less risky development programs, which has been particularly relevant for accelerating the progression of COVID-19 products.

In a recent webinar, Geraldine Venthoye, Chief Scientific Officer and Executive Vice President, Product Development at Vectura, discusses the value of inhaled drug delivery, and how repurposing or repositioning a drug can represent a safer, faster and more affordable way to develop new products than de novo drug discovery and development.

Dr. Venthoye also reviews the recent interest in inhaled COVID-19 products, choosing devices for repurposed products, device selection for repurposed biologics, and mitigating the environmental impact of devices. The webinar is available at https://bit.ly/3pdBQTD

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

Recommended

False

Related Content

What About the Kids?
Formulation
What About the Kids?

December 3, 2014

0 min read

Since the late 1990s, new regulations have given us the opportunity to address the needs of the most vulnerable and demanding patients – children...

Squid-Inspired Drug Delivery
Drug Delivery Dosage Forms Formulation
Squid-Inspired Drug Delivery

April 3, 2025

4 min read

Here’s how researchers took lessons from cephalopods to develop a new capsule that can deliver drugs, including insulin and siRNA, orally

Schizophrenia and the Future of Long-Acting Therapeutics
Formulation Dosage Forms Drug Delivery
Schizophrenia and the Future of Long-Acting Therapeutics

March 11, 2025

5 min read

Long-acting injectables help with adherence, but what if an unfolding pill could provide an oral option?

The Power of Industry and Academic Collaboration
Drug Discovery Formulation
The Power of Industry and Academic Collaboration

March 13, 2025

6 min read

Purdue University’s Young Institute is tackling pharma’s toughest challenges— from mRNA stability to aseptic manufacturing.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.